Alves, L. P. C., Fleck, M. P. A., Boni, A. and Rocha, N. S. (2017). The major depressive disorder hierarchy: Rasch analysis of 6 items of the Hamilton depression scale covering the continuum of depressive syndrome. Plos One, 12, e0170000.
American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5), 5th edn. Washington, DC: American Psychiatric Association.
Angst, J. (1961). A clinical analysis of the effects of tofranil in depression. Longitudinal and follow-up studies. Treatment of blood-relations. Psychopharmacologia, 2, 381–407.
Angst, J. (1996). The myths of psychopharmacology. In Healy, D. (ed.), The Psychopharmacologists (pp. 287–307). London: Altman, Chapman and Hall.
Bech, P. (1975). Mental illness and simulated driving: before and during treatment. Pharmakopsychiatrie Neuro-Psychopharmakologie, 8, 143–150.
Bech, P. (1993). Rating Scales for Psychopathology, Health Status and Quality of Life. A Compendium on Documentation in Accordance with the DSM-III-R and WHO Systems. Berlin: Springer.
Bech, P. (1998). Quality of Life in the Psychiatric Patient. London: Mosby-Wolfe.
Bech, P. (1999). Health-related quality of life measurements in the assessment of pain clinic results. Acta Anaesthesiologica Scandinavica, 43, 893–896.
Bech, P. (2012). Clinical Psychometrics. Oxford: Wiley Blackwell.
Bech, P. (2015). Clinical assessments of positive mental health. In Jeste, D. V. and Palmer, B. W. (eds.), Positive Psychiatry (pp. 127–143). Washington, DC: American Psychiatric Publishing.
Bech, P. (2016). Measurement-Based Care in Mental Disorders. New York: Springer.
Bech, P. et al. (1981). The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatrica Scandinavica, 63, 290–299.
Bech, P., Gram, L. F., Dein, E., Jacobsen, O., Vitger, J. and Bolwig, T. G. (1975). Quantitative rating of depressive states. Acta Psychiatrica Scandinavica, 51, 161–170.
Boyer, P. et al. (2008). Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. International Clinical Psychopharmacology, 23, 243–253.
Brown, W. A. (2013). The Placebo Effect in Clinical Practice. New York: Oxford University Press.
Brunnauer, A. et al. (2015). Driving performance and psychomotor function in depressed patients treated with agomelatine or venlafaxine. Pharmacopsychiatry, 48, 65–71.
Buckley, N. A., Dawson, A. H. and Isbister, G. K. (2014). Serotonin syndrome. BMJ, 348, g1626.
Cuijpers, P., Van Straten, A., Bohlmeijer, E., Hollon, S. D. and Andersson, G. (2010). The effects of psychotherapy for adult depression are overestimated: a meta-analysis of study quality and effect size. Psychological Medicine, 40, 211–223.
DUAG (1990). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. Journal of Affective Disorders, 18, 289–299.
DUAG (1999). Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Danish University Antidepressant Group (DUAG). Clinical Pharmacology and Therapeutics, 66, 152–165.
Elkin, I. et al. (1989). National institute of mental health treatment of depression collaborative research program. General effectiveness of treatments. Archives of General Psychiatry, 46, 971–982.
Elkin, I., Gibbons, R. D., Shea, M. T. and Shaw, B. F. (1996). Science is not a trial (but it can sometimes be a tribulation). Journal of Consulting and Clinical Psychology, 64, 92–103.
Ellervik, C., Kvetny, J. and Bech, P. (2016). The relationship between sleep length and restorative sleep in major depression: results from the Danish general suburban population study. Psychother Psychosom, 85, 45–46.
Ellervik, C., Kvetny, J., Christensen, K. S., Vestergaard, M. and Bech, P. (2014). Prevalence of depression, quality of life and antidepressant treatment in the Danish general suburban population study. Nordic Journal of Psychiatry, 68, 507–512.
Fava, G. A., Tomba, E. and Bech, P. (2017). Clinical pharmacopsychology: conceptual foundations and emerging tasks. Psychotherapy and Psychosomatics, 86, 134–140.
Feinstein, A. R. (1987). Clinometric. New Haven: Yale University Press.
Gill, T. M. and Feinstein, A. R. (1994). A critical appraisal of the quality of quality-of-life measurements. JAMA, 272, 619–626.
Guidi, J., Tomba, E. and Fava, G. A. (2016). The sequential integration of pharmacotherapy and psychotherapy in the treatment of major depressive disorder: a meta-analysis of the sequential model and a critical review of the literature. The American Journal of Psychiatry, 173, 128–137.
Hall, T., Krahn, G. L., Horner-Johnson, W., Lamb, G. and Rehabilitation Research and Training Center Expert Panel on Health Measurement (2011). Examining functional content in widely used health-related quality of life scales. Rehabilitation Psychology, 56, 94–99.
Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry, 23, 56–62.
Hamilton, M. (1967). Development of a rating scale for primary depressive illness. The British Journal of Social and Clinical Psychology, 6, 278–296.
Haq, A. U., Sitzmann, A. F., Goldman, M. L., Maixner, D. F. and Mickey, B. J. (2015). Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. The Journal of Clinical Psychiatry, 76, 1374–1384.
Hattie, J. (2009). Visible Learning. A Synthesis of Over 800 Meta-Analyses Relating to Achievement, 1st edn. London: Routhledge.
Hays, R. D., Wells, K. B., Sherbourne, C. D., Rogers, W., and Spitzer, K. (1995). Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Archives of General Psychiatry, 52, 11–19.
Jarrett, R. B., Schaffer, M., McIntire, D., Witt-Browder, A., Kraft, D. and Risser, R. C. (1999). Treatment of atypical depression with cognitive therapy or phenelzine. Archives of General Psychiatry, 56, 431–437.
Jeste, D. V., Palmer, B. W., Rettew, D. C. and Boardman, S. (2015). Positive psychiatry: its time has come. The Journal of Clinical Psychiatry, 76, 675–683.
Johnstone, E. C. et al. (1980). The Northwick Park electroconvulsive therapy trial. Lancet, 2, 1317–1320.
Kendell, R. E. (1968). The Classification of Depressive Illnesses. London: Oxford University Press.
Kendell, R. E. (1981). The present status of electroconvulsive therapy. The British Journal of Psychiatry: The Journal of Mental Science, 139, 265–283.
Kraepelin, E. (1913). Psychiatrie. Bind 3. Leipzig: Barth.
Kramer, P. D. (2016). Ordinarily Well. The Case for Antidepressants. New York: Farrar, Straus and Giroux.
Lindstrom, E., Lewander, T., Malm, U., Malt, U. F., Lublin, H. and Ahlfors, U. G. (2001). Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia.Clinical validation of a self-rating version of the UKU side effect rating scale (UKU-SERS-Pat). Nordic Journal of Psychiatry, 55 (Suppl. 44), 5–69.
Lingjaerde, O., Ahlfors, U. G., Bech, P., Dencker, S. J. and Elgen, K. (1987). The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Supplementum, 334, 1–100.
Lucas-Carrasco, R., Allerup, P. and Bech, P. (2012). The validity of the WHO-5 as an early screening for apathy in an elderly population. Current Gerontology and Geriatrics Research, 2012, 171857.
Lundquist, G. (1945). Prognosis and course in manic-depressive psychosis. Acta Psychiatrica et Neurologica Scandinavica, 38(Suppl. 35), 1–96.
Mathers, C., Fat, D. M., Boerma, J. T. and World Health Organization (2008). The Global Burden of Disease: 2004 Update. Geneva: World Health Organization.
Medical Research Council (1965). Clinical trial of the treatment of depressive illness: report to the medical research council by its clinical psychiatry committee. The British Medical Journal, 1, 881–886.
Moore, R. C., Eyler, L. T., Mills, P. J., O'hara, R. M., Wachmann, K. and Laveretsky, H. (2015). Biology of positive psychiatry. In Jeste, D. V. and Palmer, B. W. (eds.), Positive Psychiatry, 1st edn (pp. 261–283). Washington, DC: American Psychiatric Publishing.
Nyström, S. (1964). On relation between clinical factors and efficacy of ECT in depression. Acta Psychiatrica Scandinavica, 40 (Suppl. 181), 1–140.
Ottosson, J. O. (1960). Experimental studies of the mode of action of electroconvulsive therapy. Acta Psychiatrica et Neurologica Scandinavica, 35 (supplementum 145), 5–131.
Ottosson, J. O. (1985). Use and misuse of electroconvulsive treatment. Biological Psychiatry, 20, 933–946.
Rasch, G. (1980). Probablistic Models for Some Intelligence and Attainment Tests. Expanded Edition. Chicago: Chicago University Press.
Rush, A. J. et al. (1995). Clinical characteristics of outpatients with chronic major depression. Journal of Affective Disorders, 34, 25–32.
Sim, K., Lau, W. K., Sim, J., Sum, M. Y. and Baldessarini, R. J. (2016). Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials. The International Journal of Neuropsychopharmacology, 19, 1–13. doi:10.1093/ijnp/pyv076.
Timmerby, N., Andersen, J. H., Søndergaard, S., Østergaard, S. D. and Bech, P. (2017). A systematic review of the clinometric properties of the 6-item version of the Hamilton depression rating scale (HAM-D6). Psychother Psychosom, 86, 141–149.
Topp, C. W., Ostergaard, S. D., Sondergaard, S. and Bech, P. (2015). The WHO-5 well-being index: a systematic review of the literature. Psychotherapy and Psychosomatics, 84, 167–176.
UK ECT Review Group (2003). Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet, 361, 799–808.
Veldhuijzen, D. S. et al. (2006). Acute and subchronic effects of amitriptyline 25 mg on actual driving in chronic neuropathic pain patients. Journal of Psychopharmacology, 20, 782–788.
Wisniewski, S. R., Rush, A. J., Balasubramani, G. K., Trivedi, M. H., Nierenberg, A. A. and STARD Investigators (2006). Self-rated global measure of the frequency, intensity, and burden of side effects. Journal of Psychiatric Practice, 12, 71–79.
World Health Organization (1992). International Classification of Disease. Tenth Revision (ICD-10).Clinical Description and Diagnostic Guidelines. Geneva: World Health Organization.